Dasatinib-Induced Nephrotic-Range Proteinuria

被引：35

作者：

Wallace, Eric ^{[1
]}

Lyndon, William ^{[2
]}

Chumley, Phillip ^{[1
]}

Jaimes, Edgar A. ^{[1
,3
]}

Fatima, Huma ^{[4
]}

机构：

[1] Univ Alabama Birmingham, Div Nephrol, Birmingham, AL USA

[2] Nephrol Associates PC, Birmingham, AL USA

[3] VA Med Ctr, Birmingham, AL USA

[4] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2013年 / 61卷 / 06期

关键词：

Dasatinib; vascular endothelial growth factor; proteinuria; focal adhesion kinase; phosphopaxillin; ENDOTHELIAL GROWTH-FACTOR; PREECLAMPSIA-LIKE SYNDROME; DIABETIC-NEPHROPATHY; KINASE INHIBITORS; RENAL-FAILURE; IMATINIB; HYPERTENSION; EXPRESSION; SUNITINIB; BEVACIZUMAB;

D O I：

10.1053/j.ajkd.2013.01.022

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Since the introduction of imatinib, tyrosine kinase inhibition has been a mainstay in the treatment of many malignancies. The number of these medications is growing, as are the number of targeted tyrosine kinases. Off-target effects of these medications can have beneficial or adverse effects on the kidney. The onus of knowing the implications of these medications on kidney function, and appropriate treatment when such adverse effects occur, is on the nephrologist. We present a patient with chronic myelogenous leukemia who developed nephrotic-range proteinuria after initiation on dasatinib therapy that resolved after changing therapy to imatinib. The mechanism of kidney injury caused by dasatinib has not been described previously in the literature. We provide a review of vascular endothelial growth factor and its pharmacologic inhibition as it pertains to kidney pathology and propose possible mechanisms by which dasatinib induces kidney injury. (c) 2013 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

引用

页码：1026 / 1031

页数：6

共 45 条

[1] Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy [J].

Advani, Andrew ;

Wiggins, Kathryn J. ;

Cox, Alison J. ;

Zhang, Yuan ;

Gilbert, Richard E. ;

Kelly, Darren J. .

NEPHROLOGY, 2011, 16 (06) :573-581

[2] Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with Neovascular age-related macular degeneration [J].

Apte, Rajendra S. .

OPHTHALMOLOGY, 2007, 114 (09) :1702-1712

[3] Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation [J].

Bailey, E ;

Bottomley, MJ ;

Westwell, S ;

Pringle, JH ;

Furness, PN ;

Feehally, J ;

Brenchley, PEC ;

Harper, SJ .

JOURNAL OF CLINICAL PATHOLOGY, 1999, 52 (10) :735-738

[4] Vascular Endothelial Growth Factor Receptor 2 Direct Interaction with Nephrin Links VEGF-A Signals to Actin in Kidney Podocytes [J].

Bertuccio, Claudia ;

Veron, Delma ;

Aggarwal, Pardeep K. ;

Holzman, Lawrence ;

Tufro, Alda .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (46) :39933-39944

[5] Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib [J].

Bollee, Guillaume ;

Patey, Natacha ;

Cazajous, Geraldine ;

Robert, Caroline ;

Goujon, Jean-Michel ;

Fakhouri, Fadi ;

Bruneval, Patrick ;

Noel, Laure-Helene ;

Knebelmann, Bertrand .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (02) :682-685

[6] Safety Implications of Vascular Endothelial Growth Factor Blockade for Subjects Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapies [J].

Csaky, Karl ;

Do, Diana V. .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (05) :647-656

[7] Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors [J].

Demetri, George D. ;

Lo Russo, Patricia ;

MacPherson, Lain R. J. ;

Wang, Ding ;

Morgan, Jeffrey A. ;

Brunton, Valerie G. ;

Paliwal, Prashni ;

Agrawal, Shruti ;

Voi, Maurizio ;

Evan, T. R. Jeffry .

CLINICAL CANCER RESEARCH, 2009, 15 (19) :6232-6240

[8] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[9] Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases [J].

Eremina, V ;

Sood, M ;

Haigh, J ;

Nagy, A ;

Lajoie, G ;

Ferrara, N ;

Gerber, HP ;

Kikkawa, Y ;

Miner, JH ;

Quaggin, SE .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (05) :707-716

[10] VEGF inhibition and renal thrombotic microangiopathy [J].

Eremina, Vera ;

Jefferson, J. Ashley ;

Kowalewska, Jolanta ;

Hochster, Howard ;

Haas, Mark ;

Weisstuch, Joseph ;

Richardson, Catherine ;

Kopp, Jeffrey B. ;

Kabir, M. Golam ;

Backx, Peter H. ;

Gerber, Hans-Peter ;

Ferrara, Napoleone ;

Barisoni, Laura ;

Alpers, Charles E. ;

Quaggin, Susan E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1129-1136

← 1 2 3 4 5 →